Navigation Links
Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Date:6/26/2009

DEERFIELD, Ill., June 26, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary received on June 26 (U.S. time) a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In recent months, the FDA and Takeda have been in discussions about conducting an additional cardiovascular study for alogliptin.

As previously announced on March 6, 2009, the FDA informed Takeda that, although the alogliptin NDA was filed prior to the release of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes," the FDA did not believe that the amount of existing alogliptin clinical data was sufficient to meet certain statistical requirements outlined in that Guidance. The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA Guidance.

"Takeda will continue to promote key initiatives in order to realize sustained growth from a medium- to long-term perspective," said Takeda President & CEO, Yasuchika Hasegawa.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its co
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 DUSA Pharmaceuticals...mpany that is developing and marketing Levulan(... focused on patients with common skin conditions, ...utive Officer, will present a corporate overview a... Tuesday, November 10, 2009 at 10:00 a.m. ET at th...
(Date:11/6/2009)...6 Kaiser Foundation Health Plan, I...ir subsidiaries reported today a combined total op...nded September 30, 2009, compared to $10.2 billion...me in the third quarter was $336 million, compared.... Net non-operating income was $233 million in the...
(Date:11/6/2009)...swire-FirstCall/ -- Caraco Pharmaceutical Laborato...ac tromethamine ophthalmic solution, 0.5% followin...istration (FDA) for Sun Pharma,s Abbreviated New D...hthalmic solution on the first day following paten...eutically equivalent to Acular® Ophthalmic So...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Skin like tissue developed from human embryonic stem cells 9295 1Skin like tissue developed from human embryonic stem cells 9295 2HIMSS Electronic Health Record Association Elects New Leadership 52251 1HIMSS Electronic Health Record Association Elects New Leadership 52251 2HIMSS Electronic Health Record Association Elects New Leadership 52251 3Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 1Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 2Fujifilms New Digital X Ray System Designed to Eliminate Barriers to Digital Adoption 52246 3
... early non-responders unlikely to subsequently,res... may benefit,from earlier change in treatment stra...ewswire-FirstCall/,-- New data presented at the 20...h (ICOSR) suggest that antipsychotic drug,response...d,challenge the current schizophrenia treatment pa...
...Duckworth, M.D., Medical Director National,Allianc...02, 2007 /PRNewswire-USNewswire/ -- Today,the Arch...e,effectiveness of psychosocial treatments for bip...r Disorder." This is a follow up,study to one rele...edicine on the effects of antidepressants in the t...
Other Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6Latest NIMH Study on Bipolar Disorder 2Latest NIMH Study on Bipolar Disorder 3
(Date:11/7/2009)... a growing problem across the U.S. , , S... students at four-year colleges do it regularly (a...g -- downing five or more alcoholic drinks at a si...lcohol as a drug," said Jenny Hwang, associate dea...r at Stony Brook University on Long Island, N.Y. I...
(Date:11/6/2009)... COM , VANCOUVER, Nov. 6 /PRNewswire-FirstCal...COM) today announced that it will report financial... 2009 on the morning of Monday, November 9, 2009. ...st at 9:00am Eastern (6:00am Pacific) on that day ...ence call, please dial 416-695-7806 or 888-789-957...
(Date:11/6/2009)...Newswire-FirstCall/ -- Centene Corporation (NYSE: ... upcoming healthcare conferences over the next few... Annual Health Care Conference, to be held Novembe...Spa in Phoenix, Centene will present Wednesday, No...and other interested parties may access Centene,s ...
(Date:11/6/2009)... Plan International, a l...fices in 66 countries around the world, has been a...health and well-being at the upcoming American Pub...p; Exposition in Philadelphia, Pennsylvania on Nov...h Association gathers organizations together to ad...
(Date:11/6/2009)...and government programs, expert says , ,...has made it more difficult than ever before for ma...ut several options are available, according to an ..., First, talk to your pharmacist, advised Carriann...sor of pharmacy practice at Butler,s College of Ph...
Breaking Medicine News(10 mins):Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Centene Corporation to Present at Upcoming Healthcare Conferences 2Health News:Plan's Expertise Highlighted at Premier Health Forum 2Health News: Pay Less for Prescription Drugs 2
...phia, PA, September 20, 2007 Pedophilia, the sexu...ant public health concern and it does not respond ...isms underlying pedophilia are not well understood...be neural circuits contributing to pedophilia. , ...
...floxacin cut recovery time by 2 months, researcher...ing the antibiotic moxifloxacin to the standard co... tuberculosis (TB) could help reduce the time need...t adding moxifloxacin increased by 17 percent the ...
...posed to secondhand smoke at home are at increased...udy in the Journal of Adolescent Health. , Our re...condhand smoke exposure could interfere with acade...c at Temple University. , Taking other known risk...
...nn., Sept. 20 George Abercrombie, president,and c...ld more than 100,Tennessee business leaders today ... a pandemic flu presents businesses with challenge...rs such as floods or tornadoes," according to Aber...
...., Sept. 20 Approximately 100,corporate pilots an...o earn,lifesaving certifications provided by the A...the 2007 Bombardier Safety Standdown in Wichita, K... this year,s,event, medical education, expertise a...
..., N.J., Sept. 19, 2007 -- A single dose of Otsukas...pressin receptor antagonist, resulted in favorable...cant increase in urine output in patients with adv...e (ECLIPSE), presented at the late breaking trials...
Other Medicine News:Health News:Pedophilia patients are found to have deficits in brain activation 2Health News:Newer Antibiotic Speeds TB Healing 2Health News:Secondhand smoke increases teen test failure 2Health News:CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO Addresses Tennessee Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 2Health News:MedAire to Provide Medical Training for Bombardier Safety Standdown 3Health News:ECLIPSE data on effects of Otsuka's investigational novel treatment, Tolvaptan 2
Hough Fascia Knife
Paparella Elevator Knife
Austin Duckbill Knife Elevator
Friesner Ear Knife With Protector
Medicine Products: